The Apolipoprotein ε4 Allele Determines Prognosis and the Effect on Prognosis of Simvastatin in Survivors of Myocardial Infarction

Abstract

Background-Carriers of the ⑀4 allele of the apolipoprotein E gene are at a higher risk of coronary heart disease than individuals with other genotypes. We examined whether the risk of death or a major coronary event in survivors of myocardial infarction depended on apolipoprotein E genotype and whether the benefits of treatment with simvastatin differed between genotypes. Methods and Results-Cox proportional hazards models were used to analyze 5.5 years of follow-up data from 966 Danish and Finnish myocardial infarction survivors enrolled in the Scandinavian Simvastatin Survival Study. A total of 16% of the 166 ⑀4 carriers in the placebo group died compared with 9% of the 312 patients without the allele, which corresponds to a mortality risk ratio of 1.8 (95% confidence interval, 1.1 to 3.1). The risk ratio was unaffected by considerations of sex, age, concurrent angina, diabetes, smoking, and serum lipids in multivariate analyses. Simvastatin treatment reduced the mortality risk to 0.33 (95% confidence interval, 0.16 to 0.69) in ⑀4 carriers and to 0.66 (95% confidence interval, 0.35 to 1.24) in other patients (Pϭ0.23 for treatment by genotype interaction). Apolipoprotein E genotype did not predict the risk of a major coronary event.Baseline serum levels of lipoprotein(a) also predicted mortality risk and could be combined with ⑀4-carrier status to define 3 groups of patients with different prognoses and benefits from treatment. Conclusions-Myocardial infarction survivors with the ⑀4 allele have a nearly 2-fold increased risk of dying compared with other patients, and the excess mortality can be abolished by treatment with simvastatin. (Circulation.

Harmful Effects of Increased LDLR Expression in Mice With Human APOE*4 But Not APOE*3

“…34,35 Clinical studies clearly indicate that statin therapies reduce the risk of cardiovascular disease in humans, including those with apoE4, and no serious adverse effects on plasma lipids have been reported. 35,36 Nevertheless, our observations suggest the need for additional studies of the interaction between the cholesterol-lowering effect of statins and genetic variations.…”

ApoE isoform leading to hypertriglyceridemia in new onset type 1 diabetes

“…This in turn leads to a higher VLDL to HDL ratio which is pro‐atherogenic 13. This ultimately leads to carriers of the ApoE4 allele having a twofold increase in their mortality risk, as found in one study of myocardial infarction survivors 16. ApoE2 exhibits impaired binding of lipoproteins to the LPL receptor which leads to a decreased clearance of TG‐rich lipoproteins.…”

APOE gene polymorphisms and response to statin therapy

“…However, studies that investigated the clinical outcomes (mortality or composite cardiovascular events) showed significant benefit from statin treatment irrespective of APOE genotype effect. 7,34,35 In view of these results, the APOE genotype and statin treatment interactions do not reproducibly explain a clinically relevant amount of treatment response variability needed to justify implementation of a pharmacogenetic test before initiation of treatment. Until data from rigorous pharmacogenomic investigations provide solid evidence regarding the role of genetic variants in predicting statin efficacy and toxicity, there is little reason…”